botulinum toxin A + ropivacaïne — Competitive Intelligence Brief

botulinum toxin A + ropivacaïne (botulinum toxin A + ropivacaïne) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Local anesthetic. Area: Pain management.

phase 3 Local anesthetic Sodium channels Pain management Small molecule

Target snapshot

botulinum toxin A + ropivacaïne (botulinum toxin A + ropivacaïne) — Nantes University Hospital. Botulinum toxin A blocks the release of acetylcholine, a neurotransmitter that causes muscle contraction, while ropivacaine is a local anesthetic that blocks sodium channels to prevent nerve impulses.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
botulinum toxin A + ropivacaïne TARGET	botulinum toxin A + ropivacaïne	Nantes University Hospital	phase 3	Local anesthetic	Sodium channels
MEXILETINE HYDROCHLORIDE	MEXILETINE HYDROCHLORIDE		marketed		sodium channels	1985-01-01
Cordarone	AMIODARONE	Pfizer	marketed	Antiarrhythmic	sodium channels, potassium channels, calcium channels	1985-01-01
Norpace Cr	Disopyramide Phosphate	Pfizer	marketed	Type 1 antiarrhythmic	Cardiac sodium channels; cardiac cells with augmented automaticity	1977-01-01
Bupivacaine Hydrochloride	Bupivacaine Hydrochloride	Pfizer	marketed	Amide-type local anesthetic	Nerve sodium channels	1972-01-01
Bupivacaine Hydrochloride And Epinephrine	Bupivacaine Hydrochloride	Pfizer	marketed	Amide local anesthetic	Nerve sodium channels	1972-01-01
Bupivacaine Hydrochloride And Epinephrine	Bupivacaine Hydrochloride	Pfizer	marketed	Local anesthetic	Sodium channels	1972-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

• 2029-05-20 — Bupivacaine Hydrochloride · RE47826 · US
• 2034-03-13 — Bupivacaine Hydrochloride · 10398686 · US
• 2034-03-13 — Bupivacaine Hydrochloride · 11253504 · US
• 2034-03-13 — Bupivacaine Hydrochloride · 9592227 · US
• 2034-03-13 — Bupivacaine Hydrochloride · 9744163 · US
• 2034-03-13 — Bupivacaine Hydrochloride · 9913909 · US
• 2035-04-20 — Bupivacaine Hydrochloride · 9694079 · US
• 2035-04-20 — Bupivacaine Hydrochloride · 9801945 · US
• 2035-04-20 — Bupivacaine Hydrochloride · 10098957 · US
• 2035-04-20 — Bupivacaine Hydrochloride · 10213510 · US
• 2035-04-20 — Bupivacaine Hydrochloride · 10632199 · US
• 2035-04-20 — Bupivacaine Hydrochloride · 10898575 · US
• 2035-04-20 — Bupivacaine Hydrochloride · 10980886 · US
• 2035-04-20 — Bupivacaine Hydrochloride · 11083730 · US
• 2035-04-20 — Bupivacaine Hydrochloride · 11083797 · US
• 2035-04-20 — Bupivacaine Hydrochloride · 11413350 · US
• 2041-01-12 — Bupivacaine Hydrochloride · 11400019 · US
• 2041-01-22 — Bupivacaine Hydrochloride · 11452691 · US
• 2041-01-22 — Bupivacaine Hydrochloride · 11179336 · US
• 2041-01-22 — Bupivacaine Hydrochloride · 11278494 · US
• 2041-01-22 — Bupivacaine Hydrochloride · 11304904 · US
• 2041-01-22 — Bupivacaine Hydrochloride · 11311486 · US
• 2041-01-22 — Bupivacaine Hydrochloride · 11357727 · US
• 2041-01-22 — Bupivacaine Hydrochloride · 11426348 · US
• 2041-01-22 — Bupivacaine Hydrochloride · 11033495 · US

Sponsor landscape (Local anesthetic class)

1. University of California, San Diego · 3 drugs in this class
2. Durect · 3 drugs in this class
3. Pacira Pharmaceuticals, Inc · 3 drugs in this class
4. Wake Forest University Health Sciences · 3 drugs in this class
5. Medical University of Vienna · 3 drugs in this class
6. Imperial College London · 2 drugs in this class
7. Hvidovre University Hospital · 2 drugs in this class
8. Innocoll · 2 drugs in this class
9. George Washington University · 2 drugs in this class
10. Guy's and St Thomas' NHS Foundation Trust · 2 drugs in this class